The Battle for Diabetes Dominance
Jan 12th 2013 12:00PM
Updated Jan 13th 2013 6:35AM
The health-care industry's biggest conference just finished up, and the Fool's health-care team was keeping close watch. While much of the interest was focused on biotech outfits big and small, the industry's titans, the big pharmaceutical companies, made some noise of their own.
Our health-care bureau chief, Brenton Flynn, listened in on seven big pharmaceutical companies that made an appearance, and in the following video he outlines one of the major therapeutic areas of focus: diabetes.
What's inside Supernova?
Big Pharma stocks are a great defensive play, but if you're an investor looking for long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article The Battle for Diabetes Dominance originally appeared on Fool.com.Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.